OXB.jpg
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
05 mars 2024 07h00 HE | Oxford BioMedica plc
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024...